5.7 Immunosuppression in Renal Dysfunction

Immunosuppression in Renal Dysfunction After Liver Transplantation

Lecture Summary | Prof. Sanjaya Satapathy, MD, FAASLD

1. Main Clinical Topics Discussed

• Calcineurin inhibitor (CNI)-related nephrotoxicity following liver transplantation
• Differential diagnosis of post-transplant acute kidney injury (AKI)
• Renal-sparing immunosuppressive strategies
• Recognition and management of allograft rejection during CNI minimization

2. Key Learning Points, Guidelines, and Recommendations

Mechanisms of CNI Nephrotoxicity

• Acute/functional nephrotoxicity: Afferent arteriolar vasoconstriction → reduced renal blood flow → decreased GFR; typically reversible with dose reduction
• Chronic/structural nephrotoxicity: Prolonged CNI exposure → interstitial fibrosis and tubular atrophy → progressive CKD; largely irreversible
• Key principle: Early CNI toxicity is functional and reversible; long-term exposure causes permanent structural damage

Clinical Clues to CNI Nephrotoxicity

• Rising creatinine with bland urine sediment (no casts, hematuria, or proteinuria)
• Elevated tacrolimus or cyclosporine trough levels
• Recent initiation of CYP3A4-interacting medications (azole antifungals, macrolide antibiotics, diltiazem, grapefruit)
• Neurologic symptoms: tremor, headache, confusion (particularly with tacrolimus)
• Laboratory findings: hyperkalemia and hypomagnesemia (tubular effects)

Renal-Sparing Immunosuppressive Strategies

Strategy 1 — CNI Minimization + Mycophenolate Mofetil (MMF)

• Reduce nephrotoxic CNI dose while adding MMF for maintained immunosuppressive coverage
• Best suited for mild-to-moderate renal dysfunction
• Contraindications/cautions: active infection, leukopenia, bone marrow suppression
• Key side effects: GI toxicity (diarrhea), leukopenia

Strategy 2 — CNI Minimization + mTOR Inhibitor

• Everolimus preferred over sirolimus in early post-transplant setting (better-studied)
• Allows significant reduction in tacrolimus trough levels while maintaining immunosuppression
• Key side effects: proteinuria, hyperlipidemia, impaired wound healing
• Contraindications to mTOR inhibitors:

- Within the first month post-transplant or ongoing wound healing issues

- Significant pre-existing proteinuria

- Uncontrolled hyperlipidemia

Strategy 3 — Delayed/Reduced CNI Initiation (Early Post-Transplant AKI)

• Temporarily rely on steroids ± MMF for baseline immunosuppression
• Indicated when severe AKI occurs immediately post-operatively (ischemia-reperfusion injury, hemodynamic instability)
• Introduce/titrate tacrolimus gradually once renal function stabilizes

3. Differential Diagnosis of Post-Transplant AKI

> Board Pearl: Persistent renal dysfunction after liver transplantation is rarely true HRS. Prioritize CNI toxicity, ATN, or underlying CKD progression in the differential.

4. Practical Takeaways for Clinicians

Stepwise